

World Journal of *Gastroenterology*

Weekly Volume 31 Number 5 February 7, 2025



EDITORIAL

Christodoulidis G, Tsagkidou K, Koumarelas KE, Kouliou MN. Advances and challenges in peroral endoscopic myotomy: Safety, precision, and post-procedure management. *World J Gastroenterol* 2025; 31(5): 97574 [DOI: 10.3748/wjg.v31.i5.97574]

OPINION REVIEW

Pan Q, Xu QY, Zhang LH, He YF. What is the role of nonalcoholic fatty liver disease in pulmonary carcinoma development? *World J Gastroenterol* 2025; 31(5): 97500 [DOI: 10.3748/wjg.v31.i5.97500]

REVIEW

Paul JK, Azmal M, Haque ASNB, Meem M, Talukder OF, Ghosh A. Unlocking the secrets of the human gut microbiota: Comprehensive review on its role in different diseases. *World J Gastroenterol* 2025; 31(5): 99913 [DOI: 10.3748/wjg.v31.i5.99913]

ORIGINAL ARTICLE**Retrospective Study**

Zhang PC, Wang SH, Li J, Wang JJ, Chen HT, Li AQ. Clinicopathological features and treatment of gastrointestinal schwannomas. *World J Gastroenterol* 2025; 31(5): 101280 [DOI: 10.3748/wjg.v31.i5.101280]

Zhang Y, Shi K, Feng Y, Wang XB. Machine learning model using immune indicators to predict outcomes in early liver cancer. *World J Gastroenterol* 2025; 31(5): 101722 [DOI: 10.3748/wjg.v31.i5.101722]

Sun ZG, Chen SX, Sun BL, Zhang DK, Sun HL, Chen H, Hu YW, Zhang TY, Han ZH, Wu WX, Hou ZY, Yao L, Jie JZ. Important role of lymphovascular and perineural invasion in prognosis of colorectal cancer patients with N1c disease. *World J Gastroenterol* 2025; 31(5): 102210 [DOI: 10.3748/wjg.v31.i5.102210]

Yao ZY, Ma X, Cui YZ, Liu J, Han ZX, Song J. Impact of triglyceride-glucose index on the long-term prognosis of advanced gastric cancer patients receiving immunotherapy combined with chemotherapy. *World J Gastroenterol* 2025; 31(5): 102249 [DOI: 10.3748/wjg.v31.i5.102249]

Clinical Trials Study

Ovadia B, Niv E, Stern Katie S, Mahajna E, Gal O, Kopelman Y. Effect of Modulen vs budesonide on clinical response and mucosal healing in Crohn's patients. *World J Gastroenterol* 2025; 31(5): 100238 [DOI: 10.3748/wjg.v31.i5.100238]

Basic Study

Mi L, Zhang K, Ma JX, Yao JF, Tong YL, Bao ZJ. Hollow cerium nanoparticles synthesized by one-step method for multienzyme activity to reduce colitis in mice. *World J Gastroenterol* 2025; 31(5): 98732 [DOI: 10.3748/wjg.v31.i5.98732]

Li LJ, Wu CQ, Ye FL, Xuan Z, Zhang XL, Li JP, Zhou J, Su ZZ. Histopathological diagnosis of microvascular invasion in hepatocellular carcinoma: Is it reliable? *World J Gastroenterol* 2025; 31(5): 98928 [DOI: 10.3748/wjg.v31.i5.98928]

LETTER TO THE EDITOR

Tsukanov VV, Vasyutin AV, Tonkikh JL. Risk factors, prevention and screening of colorectal cancer: A rising problem. *World J Gastroenterol* 2025; 31(5): 98629 [DOI: [10.3748/wjg.v31.i5.98629](https://doi.org/10.3748/wjg.v31.i5.98629)]

Xie WT, Yang H, Bai L, Wu FF. New perspectives and prospects for the next generation of combination therapy in inflammatory bowel disease. *World J Gastroenterol* 2025; 31(5): 99462 [DOI: [10.3748/wjg.v31.i5.99462](https://doi.org/10.3748/wjg.v31.i5.99462)]

Dell'Unto E, Panzuto F, Esposito G. Rectal neuroendocrine tumors: Can we predict their behavior? *World J Gastroenterol* 2025; 31(5): 101150 [DOI: [10.3748/wjg.v31.i5.101150](https://doi.org/10.3748/wjg.v31.i5.101150)]

Lu JJ, Chen YZ, Huang YP. Critical assessment of the reported bidirectional associations between gallstone, non-alcoholic fatty liver, and kidney stone diseases. *World J Gastroenterol* 2025; 31(5): 102047 [DOI: [10.3748/wjg.v31.i5.102047](https://doi.org/10.3748/wjg.v31.i5.102047)]

Moore S, Donlon NE. Improving gastrointestinal scoring systems for predicting short-term mortality in critically ill patients. *World J Gastroenterol* 2025; 31(5): 102622 [DOI: [10.3748/wjg.v31.i5.102622](https://doi.org/10.3748/wjg.v31.i5.102622)]

Tawheed A, Ismail A, Amer MS, Elnahas O, Mowafy T. Capsule endoscopy: Do we still need it after 24 years of clinical use? *World J Gastroenterol* 2025; 31(5): 102692 [DOI: [10.3748/wjg.v31.i5.102692](https://doi.org/10.3748/wjg.v31.i5.102692)]

ABOUT COVER

Editorial Board Member of *World Journal of Gastroenterology*, John K Triantafillidis, MD, PhD, FEBGH, Associate Professor of Medicine, Staff Physician, Iasi University of Medicine and Pharmacy, Romania, "Metropolitan General" Hospital, Holargos, Athens 15562, Greece. jktrian@gmail.com

AIMS AND SCOPE

The primary aim of *World Journal of Gastroenterology* (*WJG*, *World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. *WJG* mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING

The *WJG* is now abstracted and indexed in Science Citation Index Expanded (SCIE), MEDLINE, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2024 edition of Journal Citation Reports® cites the 2023 journal impact factor (JIF) for *WJG* as 4.3; Quartile: Q1. The *WJG*'s CiteScore for 2023 is 7.8.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Wen-Bo Wang*; Production Department Director: *Si Zhao*; Cover Editor: *Jia-Ru Fan*.

NAME OF JOURNAL

World Journal of Gastroenterology

ISSN

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

LAUNCH DATE

October 1, 1995

FREQUENCY

Weekly

EDITORS-IN-CHIEF

Andrzej S Tarnawski

EXECUTIVE ASSOCIATE EDITORS-IN-CHIEF

Jian-Gao Fan (Chronic Liver Disease)

EDITORIAL BOARD MEMBERS

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

PUBLICATION DATE

February 7, 2025

COPYRIGHT

© 2025 Baishideng Publishing Group Inc

PUBLISHING PARTNER

Shanghai Pancreatic Cancer Institute and Pancreatic Cancer Institute, Fudan University
Biliary Tract Disease Institute, Fudan University

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

POLICY OF CO-AUTHORS

<https://www.wjgnet.com/bpg/GerInfo/310>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

PUBLISHING PARTNER'S OFFICIAL WEBSITE

<https://www.shca.org.cn>
<https://www.zs-hospital.sh.cn>

Critical assessment of the reported bidirectional associations between gallstone, non-alcoholic fatty liver, and kidney stone diseases

Jing-Jing Lu, Yuan-Zhi Chen, Yuan-Peng Huang

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's classification

Scientific Quality: Grade A, Grade B, Grade B

Novelty: Grade B, Grade B, Grade B

Creativity or Innovation: Grade B, Grade B, Grade B

Scientific Significance: Grade B, Grade B, Grade B

P-Reviewer: Chen GB; Liu K

Received: October 8, 2024

Revised: November 26, 2024

Accepted: December 6, 2024

Published online: February 7, 2025

Processing time: 83 Days and 1.2 Hours



Jing-Jing Lu, Yuan-Peng Huang, Department of Internal Medicine, Xiamen Hospital of Traditional Chinese Medicine, The Affiliated with Fujian University of Traditional Chinese Medicine, Xiamen 361015, Fujian Province, China

Jing-Jing Lu, Yuan-Peng Huang, The Eighth School of Clinical Medicine Xiamen Hospital, Beijing University of Chinese Medicine, Xiamen 361015, Fujian Province, China

Yuan-Zhi Chen, School of Public Health, Xiamen University, Xiamen 361102, Fujian Province, China

Co-corresponding authors: Yuan-Zhi Chen and Yuan-Peng Huang.

Corresponding author: Yuan-Zhi Chen, PhD, Postdoctoral Fellow, School of Public Health, Xiamen University, No. 4221-117 Xiang'an South Road, Xiang'an District, Xiamen 361102, Fujian Province, China. chenyuanzhi939@gmail.com

Abstract

The recent article by Jiang *et al* published in *World Journal of Gastroenterology* reports substantial bidirectional associations between gallstone disease (GSD), non-alcoholic fatty liver disease (NAFLD), and kidney stone disease (KSD), based on multicenter cross-sectional studies and a systematic review with meta-analysis. While the findings have the potential to significantly impact clinical and preventive strategies, several methodological issues merit closer examination. This letter critiques key aspects of the study, including sample population heterogeneity, potential confounding variables, and the reliance on cross-sectional data that may limit causal inferences. We also discuss the generalizability of these results to broader populations given the study's focus on the Chinese demographic. By addressing these concerns, we suggest a more nuanced interpretation of the associations between GSD, NAFLD, and KSD, advocating for longitudinal studies to validate these findings and enhance their applicability in global health contexts.

Key Words: Gallstone disease; Non-alcoholic fatty liver disease; Kidney stone disease; Bidirectional associations; Meta-analysis

©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: This study by Jiang *et al* examines the bidirectional associations between gallstone disease, non-alcoholic fatty liver disease, and kidney stone disease through multicenter cross-sectional research and meta-analysis. It highlights critical insights into the interconnected pathophysiology of these prevalent disorders. While promising for integrative medical strategies, the findings also underscore the challenges posed by heterogeneous samples and cross-sectional data limitations. The need for robust, longitudinal research to confirm these associations and extend their relevance to diverse global populations is crucial.

Citation: Lu JJ, Chen YZ, Huang YP. Critical assessment of the reported bidirectional associations between gallstone, non-alcoholic fatty liver, and kidney stone diseases. *World J Gastroenterol* 2025; 31(5): 102047

URL: <https://www.wjgnet.com/1007-9327/full/v31/i5/102047.htm>

DOI: <https://dx.doi.org/10.3748/wjg.v31.i5.102047>

TO THE EDITOR

The recent article by Jiang *et al*[1] presents findings of significant clinical interest, suggesting substantial bidirectional associations among gallstone disease (GSD), non-alcoholic fatty liver disease (NAFLD), and kidney stone disease (KSD) through multicenter cross-sectional studies and a systematic review with meta-analysis. While these findings could have significant impact on clinical practice and preventive health strategies, several methodological issues require closer examination to allow for more nuanced interpretations of the associations between these three conditions.

Exploring the bidirectional associations between GSD, NAFLD, and KSD holds substantial potential significance across multiple dimensions of healthcare and medical science. GSD is a chronic recurrent hepatobiliary condition that ranks as one of the most common gastrointestinal disorders worldwide[2,3]. However, there was significant variability in diagnostic criteria for all three diseases in the study by Jiang *et al*[1], particularly in ultrasonography across different centers. For example, the criteria for diagnosing NAFLD can vary significantly, from the simple presence of fat to more specific criteria involving liver stiffness measurements, which are not universally available[4]. Similarly, the diagnosis of kidney stones often depends on detection method, whether computed tomography, ultrasound, or X-ray, each with varying sensitivities and specificities[5]. This variation can lead to inconsistencies in reported incidences across studies. We propose that future research should strive to standardize diagnostic approaches and criteria to enhance consistency and reliability of data across different clinical settings.

GSD pathogenesis involves impaired metabolism of cholesterol, bilirubin, and bile acids, leading to the formation of gallstones within the hepatic bile duct, common bile duct, or gallbladder. Understanding the interconnections between GSD and other metabolic disorders could provide critical insights into broader metabolic dysfunctions and suggest more integrated approaches for treatment and prevention[6].

NAFLD is another prevalent metabolic disorder characterized by the accumulation of triglycerides in hepatocytes, occurring independently of causes like excessive alcohol consumption, viral or autoimmune hepatitis, or iron overload. Its severity varies, ranging from benign asymptomatic fatty steatosis to more severe forms like steatohepatitis, which can progress to fibrosis, cirrhosis, and even hepatocellular carcinoma[7,8]. Investigating how NAFLD relates to other prevalent conditions such as GSD and KSD might illuminate shared metabolic pathways and risk factors, enhancing our ability to effectively manage or intervene in these conditions.

Lastly, KSD is one of the oldest recognized medical conditions, yet its underlying metabolic mechanisms and the exact process of stone formation remain elusive. Kidney stones result from complex metabolic changes affecting various substances, suggesting a multifactorial etiology[9].

By examining the potential bidirectional relationships with GSD and NAFLD, researchers could identify novel metabolic or genetic markers that influence kidney stone formation, potentially leading to innovative preventive and therapeutic strategies. The published article presents a multicenter cross-sectional study, systematic review, and meta-analysis, utilizing data from subjects at Jinshan Hospital of the First Affiliated Hospital of Chongqing Medical University (urban Chongqing), Kaizhou District People's Hospital of Chongqing (rural Chongqing), Beijing Xiaotangshan Hospital, and Tianjin Medical University Cancer Institute and Hospital. It examines pairwise relationships between GSD, NAFLD, and KSD.

Of major concern is the study's reliance on cross-sectional data to infer causality between GSD, NAFLD, and KSD. While the authors provide valuable insights into disease prevalence, cross-sectional studies inherently lack the temporal perspective required to establish directionality and causality of these relationships[10,11]. This limitation is critical, as the bidirectional nature of disease associations suggests a complex interplay that could be better explored through longitudinal research designs. Such studies would allow for the observation of the diseases over time, offering stronger evidence of causality rather than mere association. Such studies should also include a comprehensive set of potential confounding variables including body mass index, dietary habits, genetic predispositions, and socioeconomic status, which could significantly influence disease outcomes.

Another significant issue in the study is the variability in diagnostic criteria across the multiple centers. While ultrasonography is practical, it may not consistently capture the nuanced presentations of NAFLD and KSD across different settings and operators. The potential for diagnostic misclassification is a notable risk that could lead to biased results. We suggest that future studies incorporate more consistent diagnostic standards across multiple centers to reduce

variability and improve the reliability of findings. Moreover, the heterogeneity of sample populations, spanning various regions within China, raises questions about the consistency of healthcare practices, access to medical services, and environmental or lifestyle factors that might influence the prevalence and detection of these diseases.

The study's focus on a predominantly Chinese population complicates the generalizability of the findings. The epidemiology of GSD, NAFLD, and KSD can significantly vary across different ethnicities and geographic regions due to genetic, dietary, and lifestyle factors. Thus, while the study presents valuable data, its applicability to other populations remains uncertain. To enhance the relevance of these findings globally, replication studies with diverse demographic settings are necessary. For instance, the genetic factors influencing cholesterol and bile acid metabolism, which are critical in GSD pathogenesis, may significantly differ between populations. Certain genetic polymorphisms associated with GSD in Asian populations may not be as prevalent or may have different effects in Caucasian or African populations. Similarly, dietary factors, such as the high consumption of high-fructose corn syrup in Western diets, have been linked to higher rates of NAFLD in these populations compared to Asian diets, which tend to be lower in fructose.

To validate the findings of Jiang *et al*[1] in non-Chinese populations, it is crucial to perform replication studies that are designed to consider these regional and ethnic variations. By addressing these aspects, future research can enhance the global relevance of the findings and contribute to a more nuanced understanding of how GSD, NAFLD, and KSD are interconnected. This broader understanding is essential for developing targeted prevention and treatment strategies that are effective across diverse global populations. Additionally, investigation into biomarkers that could help establish causal links between these diseases offers promising directions for future research. Biomarkers such as C-reactive protein for inflammation, liver enzymes for NAFLD, and urinary markers for KSD could provide more definitive evidence of disease mechanisms and progression[6,12,13]. These biomarkers could potentially streamline diagnosis and enable earlier therapeutic intervention, thereby improving patient outcomes.

If the reported bidirectional associations are validated, they could transform current approaches to screening, diagnosing, and managing these common but often compartmentalized diseases. Recognizing interconnected pathways may promote the development of integrated treatment protocols and preventive measures. However, the translation of these findings into clinical practice requires rigorous validation of the results through methodologically sound research, ideally longitudinal in nature, to confirm these preliminary observations[14].

In conclusion, Jiang *et al*[1] provide important preliminary insights into the interconnected nature of GSD, NAFLD, and KSD. However, addressing the concerns of methodological rigor, diagnostic accuracy, and population diversity through well-designed follow-up studies will be crucial for advancing our understanding of these diseases and effectively translating research findings into practice. Therefore, further understanding the bidirectional associations among these diseases is not only a pursuit of academic interest but also a crucial step towards a more holistic understanding of metabolic diseases. This exploration could ultimately lead to breakthroughs in how these common and burdensome diseases are predicted, prevented, and treated, thereby reducing their extensive impact on global health.

FOOTNOTES

Author contributions: Lu JJ, Chen YZ and Huang YP were responsible for the conceptualization, evidence validation, writing of the original draft, and review and editing of each subsequent version; Chen YZ and Huang YP provided overall supervision of the project.

Supported by The National Natural Science Foundation of China, No. 82074508; Fujian Provincial Natural Science Foundation, No. 2023J011627; Fujian Provincial Health and Wellness Science and Technology Plan Project, No. 2023CXB003; Xiamen City Support for the Development of Traditional Chinese Medicine Special TCM Scientific Research Project, No. XWZY-2023-0603; and The Seventh Batch of National Famous Old Traditional Chinese Medicine Experts Experience Heritage Construction Program of National Administration of TCM, No. 76 (2022).

Conflict-of-interest statement: The authors declare that they have no conflicts of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country of origin: China

ORCID number: Jing-Jing Lu 0009-0001-5349-9533; Yuan-Zhi Chen 0000-0003-3627-5551.

S-Editor: Liu H

L-Editor: A

P-Editor: Yu HG

REFERENCES

- Jiang G, Li S, Li H, Xie L, Li S, Yan Z, Yu W, Luo J, Bai X, Kong L, Lou Y, Zhang C, Li G, Shan X, Mao M, Wang X. Bidirectional

- associations among gallstone disease, non-alcoholic fatty liver disease, kidney stone disease. *World J Gastroenterol* 2024; **30**: 4914-4928 [DOI: [10.3748/wjg.v30.i46.4914](https://doi.org/10.3748/wjg.v30.i46.4914)]
- 2 **Marschall HU**, Einarsson C. Gallstone disease. *J Intern Med* 2007; **261**: 529-542 [PMID: [17547709](https://pubmed.ncbi.nlm.nih.gov/17547709/) DOI: [10.1111/j.1365-2796.2007.01783.x](https://doi.org/10.1111/j.1365-2796.2007.01783.x)]
 - 3 **Patel H**, Jepsen J. Gallstone Disease: Common Questions and Answers. *Am Fam Physician* 2024; **109**: 518-524 [PMID: [38905549](https://pubmed.ncbi.nlm.nih.gov/38905549/)]
 - 4 **Martinou E**, Pericleous M, Stefanova I, Kaur V, Angelidi AM. Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches. *Diagnostics (Basel)* 2022; **12** [PMID: [35204498](https://pubmed.ncbi.nlm.nih.gov/35204498/) DOI: [10.3390/diagnostics12020407](https://doi.org/10.3390/diagnostics12020407)]
 - 5 **Brisbane W**, Bailey MR, Sorensen MD. An overview of kidney stone imaging techniques. *Nat Rev Urol* 2016; **13**: 654-662 [PMID: [27578040](https://pubmed.ncbi.nlm.nih.gov/27578040/) DOI: [10.1038/nrurol.2016.154](https://doi.org/10.1038/nrurol.2016.154)]
 - 6 **Reshetnyak VI**. Concept of the pathogenesis and treatment of cholelithiasis. *World J Hepatol* 2012; **4**: 18-34 [PMID: [22400083](https://pubmed.ncbi.nlm.nih.gov/22400083/) DOI: [10.4254/wjh.v4.i2.18](https://doi.org/10.4254/wjh.v4.i2.18)]
 - 7 **Lazo M**, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. *Semin Liver Dis* 2008; **28**: 339-350 [PMID: [18956290](https://pubmed.ncbi.nlm.nih.gov/18956290/) DOI: [10.1055/s-0028-1091978](https://doi.org/10.1055/s-0028-1091978)]
 - 8 **Milić S**, Stimac D. Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment. *Dig Dis* 2012; **30**: 158-162 [PMID: [22722431](https://pubmed.ncbi.nlm.nih.gov/22722431/) DOI: [10.1159/000336669](https://doi.org/10.1159/000336669)]
 - 9 **Xu Z**, Yao X, Duan C, Liu H, Xu H. Metabolic changes in kidney stone disease. *Front Immunol* 2023; **14**: 1142207 [PMID: [37228601](https://pubmed.ncbi.nlm.nih.gov/37228601/) DOI: [10.3389/fimmu.2023.1142207](https://doi.org/10.3389/fimmu.2023.1142207)]
 - 10 **Savitz DA**, Wellenius GA. Can Cross-Sectional Studies Contribute to Causal Inference? It Depends. *Am J Epidemiol* 2023; **192**: 514-516 [PMID: [35231933](https://pubmed.ncbi.nlm.nih.gov/35231933/) DOI: [10.1093/aje/kwac037](https://doi.org/10.1093/aje/kwac037)]
 - 11 **Capili B**. Cross-Sectional Studies. *Am J Nurs* 2021; **121**: 59-62 [PMID: [34554991](https://pubmed.ncbi.nlm.nih.gov/34554991/) DOI: [10.1097/01.NAJ.0000794280.73744.fe](https://doi.org/10.1097/01.NAJ.0000794280.73744.fe)]
 - 12 **Noureddin M**, Loomba R. Nonalcoholic fatty liver disease: Indications for liver biopsy and noninvasive biomarkers. *Clin Liver Dis (Hoboken)* 2012; **1**: 104-107 [PMID: [31186861](https://pubmed.ncbi.nlm.nih.gov/31186861/) DOI: [10.1002/cld.65](https://doi.org/10.1002/cld.65)]
 - 13 **Brewin A**, Sriprasad S, Somani BK. Role of urinary biomarkers for diagnosis and prognosis of kidney stone disease. *Curr Opin Urol* 2021; **31**: 71-79 [PMID: [33394608](https://pubmed.ncbi.nlm.nih.gov/33394608/) DOI: [10.1097/MOU.0000000000000856](https://doi.org/10.1097/MOU.0000000000000856)]
 - 14 **Curtis K**, Fry M, Shaban RZ, Considine J. Translating research findings to clinical nursing practice. *J Clin Nurs* 2017; **26**: 862-872 [PMID: [27649522](https://pubmed.ncbi.nlm.nih.gov/27649522/) DOI: [10.1111/jocn.13586](https://doi.org/10.1111/jocn.13586)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: office@baishideng.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

